Oppenheimer lowered the firm’s price target on Regeneron (REGN) to $925 from $950 and keeps an Outperform rating on the shares. The firm is ...

Cell therapy is emerging as a cutting-edge precision treatment in ophthalmology and is gaining immense popularity worldwide among people affected by degenerative eye diseases. Traditional therapies ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

Boston Scientific makes surgical devices and medical equipment to treat ... due to wholesaler destocking. Regeneron Pharmaceuticals makes drugs to treat eye diseases, allergies, inflammation ...

Contributors to performance Boston Scientific makes surgical devices and medical equipment ... due to wholesaler destocking. Regeneron Pharmaceuticals makes drugs to treat eye diseases, allergies ...

We have an update on the One UI 7 rollout and it’s good news this time – the press release from Samsung Singapore lists more devices that will be updated to the latest Samsung software.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to ...

Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry. AMGN Stock Performance Image Source: Zacks Investment Research Amgen’s stock has been rising ...

Amgen has developed biosimilars of J&J’s Stelara (Wezlana/ABP 654), Alexion’s Soliris (Bekemv/ABP 959) and Regeneron’s Eylea (ABP 938). Wezlana was approved in 2023 and launched in January 2025.

Global biopharmaceutical leaders continue to make significant strides in retinal disease treatments; as Bayer and Regeneron make headway with its high-dose version of Eylea (Eylea HD), Roche's Vabysmo ...